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INTRODUCTION
Globoid cell leukodystrophy (GLD) or Krabbe disease is a rare, rap-
idly progressive, and severe demyelinating lysosomal storage dis-
ease (LSD) due to the deficiency of the galactocerebrosidase (GALC) 
enzyme. Since GALC is responsible for the hydrolysis of galactose 
from several glycosphingolipids involved in myelination, including 
galactosylceramide (GalCer) and its by-product galactosylsphingo-
sine (psychosine, Psy), GALC dysfunction leads to the accumulation 
of substrates in the central (CNS) and peripheral nervous system 
(PNS). In particular, the accumulation of the cytotoxic sphingolipid 
Psy in myelinating cells and neurons leads to an overt primary and 
secondary demyelination.1–3 As a consequence, patients experi-
ence progressive and severe neurological symptoms like seizures, 
sensory loss, and rapid psychomotor deterioration.4 In the early 
infantile (EI) forms, clinical decline is rapid and death occurs a few 
years after the diagnosis. Many therapeutic approaches, alone and 
in combination,5 have been attempted in the most common murine 
model of the disease (the Twitcher mouse); however, the only one 
therapy thus far applied to GLD patients, on the basis of promising 
results in preclinical studies,6–10 is transplantation of hematopoietic 
stem cells (HSCT) derived from compatible healthy donors’ bone 
marrow (BM) or umbilical cord blood (CB). If applied very early in life, 
HSCT from unrelated CB can delay the onset of GLD and attenuate 
its clinical manifestations, even if long-term disability was reported 
in the majority of the transplanted children.11,12 Transplantation 
in patients presenting overt disease symptoms failed to substan-
tially ameliorate their prognosis, and their disease progression was 
shown to be as rapid as in not-transplanted children.12 An autolo-
gous hematopoietic stem cell gene therapy approach could be of 
great relevance to overcome HSCT limited outcome since reducing 
transplant-related side effects, morbidity, and mortality could pro-
vide an added therapeutic benefit due to the potential for vector-
mediated enzyme supra-physiological expression in hematopoietic 
stem and progenitor cells (HSPCs) and their progeny.13 Since new-
born screening for GLD is not yet routinely available and the major-
ity of patients are diagnosed after symptom onset (except when an 
older, already diagnosed affected sibling is present), this strategy 
could also spare precious time for search of a compatible donor.
We have already demonstrated the potential of autologous 
HSPC-gene therapy based on lentiviral vector (LV) transduction in 
the murine model of GLD.14 In this effort, we addressed the unex-
pected issue of the toxicity of LV-mediated murine GALC (mGALC) 
supra-physiological expression in murine HSPCs but not in their 
differentiated progeny15 by exploiting a murine GALC-encoding LV 
regulated by four target sequences for micro RNA 126 (miR-126), 
which is selectively expressed into immature hematopoietic cells 
and virtually absent in mature compartments.14 We proved the effi-
cacy of this LV construct in protecting murine HSPCs from murine 
GALC overexpression-related toxicity. Moreover, the construct 
drove sustained enzyme expression up to therapeutic levels in the 
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Globoid cell leukodystrophy (GLD) is a demyelinating lysosomal storage disease due to the deficiency of the galactocerebrosidase 
(GALC) enzyme. The favorable outcome of hematopoietic stem and progenitor cell (HSPC)-based approaches in GLD and other 
similar diseases suggests HSPC gene therapy as a promising therapeutic option for patients. The path to clinical development of 
this strategy was hampered by a selective toxicity of the overexpressed GALC in the HSPC compartment. Here, we presented the 
optimization of a lentiviral vector (LV) in which miR-126 regulation was coupled to codon optimization of the human GALC cDNA 
to obtain a selective and enhanced enzymatic activity only upon transduced HSPCs differentiation. The safety of human GALC 
overexpression driven by this LV was extensively demonstrated in vitro and in vivo on human HSPCs from healthy donors. No 
perturbation in the content of proapoptotic sphingolipids, gene expression profile, and capability of engraftment and mutlilineage 
differentiation in chimeric mice was observed. The therapeutic potential of this LV was then assessed in a severe GLD murine model 
that benefited from transplantation of corrected HSPCs with longer survival and ameliorated phenotype as compared to untreated 
siblings. This construct has thus been selected as a candidate for clinical translation.
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differentiated tissue progeny of the transduced HSPCs, as shown in 
the Trs mouse model of which we substantially improved survival 
and phenotype as compared not only to untreated affected siblings 
but also to affected mice transplanted with wild type HSPCs.14
We here investigated the best LV design for a proper clinical trans-
lation of these promising preclinical results. To this purpose, we 
employed a human GALC (hGALC) transgene of which we improved 
transcript stability and enzymatic expression by codon optimiza-
tion and adjusted the number of miR-126 target sequences with 
the aim of balancing the need for repression of transgene expres-
sion in the human HSPC compartment with the requirement of sus-
tained enzyme expression upon their differentiation. Moreover, we 
confirmed that the new construct developed for clinical translation 
retains therapeutic efficacy in a severe disease animal model.
ReSUlTS
Optimization of an advanced LV construct for safe and efficient 
expression of the human GALC enzyme
In order to allow safe and efficient hGALC expression also in 
human HSPCs and their differentiated progeny, we confirmed 
the use of miR-126 posttranscriptional regulation, exploiting its 
capability to repress transgene expression in a differentiation 
stage-specific manner also in the human setting.14,16 We evalu-
ated the regulatory potential of single versus multiple miR-126 
target sequences at different stages of human HSPCs in vitro dif-
ferentiation, namely, after 1 day and 14 days of liquid culture 
after second hit of transduction (t = 0). To this purpose, three 
regulated LVs with one, two, or four target sequences of miR-
126 downstream to the hGALC cDNA were generated and tested 
on CB- and BM-derived HSPCs. Among the tested LV constructs, 
one miR-126 target (hereon referred to as hGALC_126T.LV) per-
formed at best since it allowed a highly significant (P < 0.0001) 
repression of hGALC activity in both CB- and BM-HSPCs at +1 
day of culture (Figure 1a) and a sustained hGALC expression 
upon in vitro cell differentiation (after 14 days of liquid culture) 
(Figure 1b), in the presence of comparable vector copy number 
(VCN) values with the other tested constructs (Supplementary 
Figure S1a). The slightly lower hGALC activity measured at +14 
days in the cells transduced with hGALC_126T.LV as compared 
to the unregulated construct could be ascribed to presence of 
Figure 1  Optimization of a LV for the expression of human GALC enzyme. (a) hGALC activity measured in BM- (n ≥ 4 donors) or CB- (n ≥ 7 donors) 
derived HSPCs upon transduction with hGALC.LV (no tags), hGALC_126T.LV (1x126T), hGALC_2x126T.LV (2x126T), hGALC_4x126T.LV (4x126T) or hIDUA.
LV (ctrl) at +1 day (+1d) after transduction is reported. Values are expressed as percentage relative to the activity achieved upon hGALC.LV transduction 
(dotted line = 100%) (mean ± SEM). (b) hGALC activity measured in BM- (n ≥ 2 donors) or CB- (n ≥ 10 donors) derived HSPCs upon transduction with 
above-mentioned LVs at +14 days after transduction is reported. Values are expressed as fold to normal donor (ND) level (dotted line) (mean ± SEM). 
(c) hGALC activity values measured at +14 days in BM-HSPCs (n ≥ 5) or CB- (n ≥ 6) upon hGALC_126T.LV or hGALCC.O._126T.LV transduction. Values are 
normalized for VCN and expressed as fold to normal donor (ND) level (dotted line) (mean ± SEM). Statistical analysis was performed with one-way 
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some residual miR-126 transcript in the in vitro culture prog-
eny of our cells (data not shown). Thus, hGALC activity driven 
by hGALC_126T.LV could increase further in vivo in terminally 
differentiated cells that nearly completely lose miR-126 activ-
ity. The other tested constructs provided a stronger repression 
of enzyme activity in human HSPCs, persisting to some extent 
also upon cell differentiation, thus possibly affecting therapeu-
tic enzyme delivery to affected tissues by the myeloid progeny 
of the transduced HSPCs. Importantly, the level of hGALC activ-
ity repression obtained by the use of hGALC_126T.LV in HSPCs 
was sufficient to restore the clonogenic potential of the trans-
duced cells to what observed in control cells (Supplementary 
Figure S1b).
In order to further ameliorate the stability of hGALC long tran-
script, enhance hGALC expression in differentiated cells, and 
increase the therapeutic potential of the strategy, we generated a 
new LV carrying a codon optimized human Galc cDNA regulated 
by one miR-126 target. This PGK.hGALCC.O._1x126T.LV (from here on 
referred to as hGALCC.O._126T.LV) and a control vector were tested 
on CB- and BM-HSPCs with the protocol in use in the clinics allowing 
BM-derived HSPCs efficient transduction.13 This protocol resulted 
in very high transduction efficiency in CB-HSPCs in which >8.5 
LV copies/genome were measured in the liquid culture progeny 
of the transduced cells with both tested vectors (Supplementary 
Figure  S2). Even at this high VCN, the use of the regulated LV 
encoding codon-optimized hGALC resulted in a good repression 
of hGALC activity in undifferentiated cells (+1 day; Supplementary 
Figure S3). Importantly, upon differentiation, the cells transduced 
with hGALCC.O._126T.LV showed a sustained enzyme activity, which 
was significantly higher than the activity measured in the in vitro 
progeny of HSPCs transduced with the original hGALC_126T.LV 
with a noncodon optimized transgene (Figure 1c). Of note, hGALC 
activity measured in the progeny of hGALCC.O._126T.LV transduced 
BM-derived HSPCs was equal to 14-fold the basal normal donors’ 
level (Supplementary Figure S4), confirming the high therapeutic 
potential of this regulated LV.
Figure 2 Safe hGALC over-expression in human HSPCs. (a,b) HSPCs from BM- (n = 11 replicates derived from five donors for transduced cells and n = 5 
donors for untransduced cells) and CB- (n = 6 donors) were transduced with the indicated LVs and plated for the clonogenic assay. The number (#) of 
(a) colonies and (b) differentiation toward B/CFU-E and CFU-M/GM subsets are reported (mean±SEM). (c,d) BM- (n = 9 replicates derived from three 
donors for transduced cells and n = 3 replicates derived from three donors for UT cells) and CB- (n = 6 donors) derived HSPCs transduced with indicated 
LVs were evaluated for (c) the occurrence of apoptosis and (d) maintenance of stemness markers at the end of the second hit of transduction, and after 
1 day in culture. Apoptosis was assessed by cytofluorimetric analysis using AnnexinV/7AAD markers and identifying viable cells (AnnV-7AAD-), early 
apoptotic cells (AnnV+7AAD-), late apoptotic cells (AnnV+7AAD+), and necrotic cells (AnnV-7AAD+). Average values ± SEM are reported. On viable 
cells: ****P < 0.0001, ***P < 0.001, with unpaired t-test on hGALC- versus hARSA-expressing HSPCs. Percentages of CD34+ and CD38+ relative staining 
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hGALCC.O._126T.LV drives safe hGALC overexpression in human 
HSPCs
To determine whether hGALC expression driven by the regulated 
codon optimized hGALCC.O._126T.LV construct was well tolerated by 
human HSPCs, transduced cells were extensively characterized and 
analyzed in their functionality both in vitro and in vivo. Control vec-
tor, as anticipated above, was a similar LV encoding for the human 
Arylsulfatase A (ARSA) cDNA, being ARSA the lysosomal enzyme 
acting before GALC in the sulfatide catabolic pathway, under the 
control of the same hPGK promoter but without any miRNA regula-
tion due to its safe expression profile13,17 (hARSA.LV).
BM- and CB-HSPCs transduced with hGALCC.O._126T.LV and 
control vectors were plated for colony-forming cell assay and 
Long-term Culture Initiating Cell assay (LTC-IC); a similar number 
of colony-forming cells were retrieved in all the tested conditions 
(Figure 2a and Supplementary Figure S5), with homogenous size, 
morphology, and differentiation pattern toward burst/colony-form-
ing unit-erythroid (B/CFU-E) and colony-forming unit macrophage/
granulocyte macrophage (CFU-M/GM) subsets (Figure 2b).
To exclude any latent early sign of toxicity induced by transduc-
tion and transgene expression in HSPCs, BM and CB cells were 
deeply analyzed for occurrence of apoptosis by AnnexinV/7AAD 
cytofluorimetric analysis performed soon after transduction and 
after 1 day in culture. The assessment showed comparable per-
centages of viable cells as well as early apoptotic events likely 
due to transduction in all tested conditions (Figure 2c). Moreover, 
hGALCC.O._126T.LV transduced human HSPCs showed similar surface 
marker expression as compared to control vector-transduced coun-
terparts (Figure 2d).
We previously demonstrated that GALC-mediated toxicity and 
induction of apoptosis in murine HSPCs transduced with mGALC-
expressing LV are associated with accumulation of Ceramide (in partic-
ular of C16 Ceramide, a specific well known proapoptotic  stimulus18,19) 
and related proapoptotic sphingolipids. We thus measured these 
compounds in BM-HSPCs at +1 day and +14 days after transduc-
tion with the above-referenced vectors. The sphingolipid profile did 
not substantially differ between hGALCC.O._126T.LV and control vec-
tor transduced BM-HSPCs and their in vitro progeny, suggesting that 
regulated hGALC expression does not cause a perturbation of HSPCs 
sphingolipid content at both the tested time points (Figure 3a).
To further investigate whether LV-driven hGALC regulated expres-
sion could affect physiological processes of BM-HSPCs, the expres-
sion profiles of BM-derived HSPCs transduced with hGALCC.O._126T.
LV and hARSA.LV were compared with those of untransduced (UT) 
Figure 3 Sphingolipid and gene expression profile of BM-derived HSPCs. (a) Dihydroceramide (total d18:0), ceramide (total d18:1), C16-ceramide 
(d18:1/16:0), globotriaosylceramide (Gb3), glucosyl/galactosyl ceramide (Glc/GalCer), lactosylceramide (LacCer), sphinganine (SPA), sphingosine (SPH) 
were measured at +1 day and +14 days in BM-derived HSPCs transduced as indicated. Sphingolipids concentration is expressed as pmol/μg protein 
content and values are reported on a logarithmic scale (+1 day: n = 3 donors; +14 days: n = 2 donors). (b) Unsupervised Affymetrix analysis of the gene 

























































































Gene therapy for globoid cell leukodystrophy
S Ungari et al.
Molecular Therapy — Methods & Clinical Development (2015) 15038Official journal of the American Society of Gene & Cell Therapy
cells at +1 day. Unsupervised hierarchical clustering by the dChip 
software showed a tendency to cluster in three main branches corre-
sponding to transduction triplicates, indicating that overexpression 
of hGALC and hARSA was not associated with consistent changes in 
the gene expression profile of HSPCs (Figure 3b). A supervised clus-
tering approach (fold change >2, P < 0.05) performed on hGALC and 
hARSA-transduced versus UT cells (Supplementary Figure S6a,b) 
and transduced versus UT cells (Supplementary Figure S6c) dis-
played overall 17 upregulated and 3 downregulated genes. Only 1 
gene (Slc7a11) is in common among the three analyses (a, b, and 
c). None of the deregulated genes belong to the proto-oncogene 
database20 and none of them, with the exception of hARSA, belong 
to the sphingolipid metabolism pathway (KEGG hsa00600 pathway) 
indicating that the hGALC overexpression driven by the regulated 
LV has no impact on the sphingolipid enzymatic cascade.
Regulated hGALC overexpression does not impair repopulation 
and differentiation potential of BM-HSPCs
BM-HSPCs transduced with hGALCC.O._126T.LV and control vector 
were also analyzed in vivo for their repopulation and differentia-
tion potential. Sublethally irradiated NSG mice were transplanted 
with BM-HSPCs transduced with hGALCC.O._126T.LV or with control 
vector. Mice were sacrificed 12 weeks after transplantation and 
hematopoietic organs were analyzed for human cell engraftment 
and differentiation. hGALC-transduced cells efficiently repopulated 
hematopoietic organs of all transplanted mice similar to control 
transduced cells (Figure 4a). Notably, multilineage differentiation of 
the grafted population in BM, liver, spleen, and thymus of the chi-
meric mice was observed (Figure 4b). No significant differences in 
the repopulation and differentiation capacities of hGALC- and con-
trol LV-transduced hHSPCs were noticed, thus enforcing the safety 
profile of regulated hGALC overexpression in these cells.
Functionality of hGALCC.O._126T.LV in a severe GLD mouse model
In order to confirm that this hGALCC.O._126T.LV could be employed 
for future clinical translation, we tested it in a severe murine model 
of GLD for its capability to induce the production of a functional 
protein able to clear sphingolipid storages and contribute to 
phenotype amelioration. Lineage negative HSPCs isolated from 
Twitcher mice were transduced with hGALCC.O._126T.LV and hGALC 
activity was measured at above-normal values (1.6-fold the enzyme 
activity measured in the control LV-transduced wild-type cells) 
in their culture progeny (Figure 5a). An high VCN, comparable to 
controls, was also measured in the gene-corrected murine HSPCs 
(Figure  5b), suggesting the absence of the negative selection of 
highly transduced cells previously observed upon unregulated 
mGALC overexpression.14 Moreover, murine HSPCs transduced with 
the two vectors when plated for the colony-forming cell assay gave 
rise to a comparable number of colonies, indicating the absence of 
a functional impairment (Figure 5c) and supporting the tolerability 
of regulated hGALC expression driven by hGALCC.O._126T.LV also in 
murine HSPCs.
hGALC-corrected Twitcher HSPCs were then transplanted into 
lethally irradiated p7 newborn Twitcher mice. Transplanted mice 
(-/- hGALC_126T) showed a statistically significant longer sur-
vival than untreated (UT) Twitcher mice (P = 0.0002); results were 
comparable to what observed in animals receiving wild-type con-
trol LV-transduced murine HSPCs (+/+ hARSA) (Figure 6a). This 
gain in survival was associated to a sustained engraftment of 
hGALCC.O._126T.LV-transduced cells in the BM of transplanted mice 
(Supplementary Table S1), and efficient hGALC enzyme delivery to 
the brain, spinal cord and liver, as observed in long-lived treated ani-
mals (Figure 6b). VCN measured in the BM significantly positively 
affected hGALC activity measured in brain and spinal cord and 
survival of gene therapy–treated mice (Figure 6c). These findings 
Figure 4 Engraftment and differentiation of BM-derived HSPCs in tissues of transplanted NSG mice. BM-derived HSPCs (n = 3 donors) transduced 
with hGALCC.O._126T.LV or hARSA.LV were transplanted into sublethally irradiated NSG mice (n = 16 and 15 mice, respectively). (a) The percentage of 
human CD45+cells in BM, liver, spleen, and thymus of NSG mice was evaluated 12 weeks after transplantation. (b) Mice with >1% CD45+ cells in BM 
(hGALCC.O._126T.LV: n = 16; hARSA.LV: n = 15), liver (hGALCC.O._126T.LV: n = 16; hARSA.LV: n = 15) and spleen (hGALCC.O._126T.LV: n = 10; hARSA.LV: n = 9) 
and with >5% CD45+ cells in the thymus (hGALCC.O._126T.LV: n = 5; hARSA.LV: n = 2) were considered engrafted and on these CD45+ percentages a 
lineage marker evaluation was performed, including the following markers: CD34 (stem and progenitor cells), CD13 (myeloid cells), CD15 (granulocytes), 
CD19 (B lymphocytes), CD3 (pan-T lymphocytes), CD4 (T-helper lymphocytes), CD8 (cytotoxic T lymphocytes); percent marker-positive cells was 
calculated relative to CD45+ gated cells; in the thymus, the percent of CD3+ cells was calculated among CD45+ cells and then percent of CD4+ and CD8+ 
cells (indicated by arrow) was calculated relative to CD3+ gated cells.
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were supported by the evidence of transduced cells in these tissues 
(Table S1). Along with improved survival, gene therapy–treated 
mice also experienced reduced tremors and showed an amelio-
ration of walking abilities (Figure 6d) as compared to untreated 
animals. To determine the effect of hGALC activity reconstitution 
on lysosomal storage in the nervous tissue, we visualized globoid 
cells containing undegraded sphingolipids by lectin immunofluo-
rescence. Lectin+ storage was strongly increased in Twitcher brains 
as compared to wild-type counterparts, with a rostral to caudal 
gradient reflecting disease progression (Figure 6e). In the brain of 
long-lived gene therapy–treated mice, a significant reduction of the 
storage was observed in cortex, cerebellum, and pons (Figure  6e 
and Supplementary Figure S7). Reduction was also observed in 
the sciatic nerve, suggesting a gene therapy contribution also at 
the PNS level (Figure 6e). Astrogliosis was also measured by means 
of GFAP staining in treated and control mice. While a strong GFAP 
immunopositive signal was detected in Twitcher mice in both ante-
rior and posterior brain areas, a significant reduction of the signal 
was observed in the cortex and pons of gene therapy–treated mice 
with a trend of decrease of GFAP staining also in the cerebellum 
(Figure 6f and Supplementary Figure S7). These results were com-
parable if not superior to those observed by transplanting control 
LV-transduced wild-type cells.
DISCUSSION
There is a strong rationale for the development of a safe and effec-
tive gene therapy approach for GLD based on HSPCs and LVs, given 
the favorable preliminary results obtained with this treatment in 
a similar lysosomal storage disease, metachromatic leukodystro-
phy.13 The experimental work described here contributes to the 
clinical development of such approach by addressing key feasibility, 
efficacy, and safety issues related to the expression of the hGALC 
enzyme in hematopoietic cells.
Based on our previous data obtained in the disease murine model 
employing the murine Galc cDNA and murine HSPCs,14,15 we devel-
oped a LV construct containing the target sequences of miR-126 and 
the human Galc cDNA for clinical translation. This construct allowed 
preventing enzyme expression in early murine and human HSPCs 
that are plenty of miR-126, while drove sustained GALC activity in 
their differentiated progeny that is nearly deprived of miR-126. For 
clinical translation of this strategy we then constructed and tested 
different LVs in which the murine transgene was replaced by the 
human Galc cDNA and different levels of regulation were obtained 
by varying the number of miR-126 target sequences inserted down-
stream the transgene, based on the evidence that the miR-126 
machinery is nearly fourfold more active in human versus murine 
cells.14 Interestingly, fewer miR-126 target sequences were enough 
to obtain a strong repression of human GALC expression in human 
HSPCs as compared to murine cells. These data are supported by 
the recent preclinical testing of a miR-126 regulated LV for the treat-
ment of X-linked chronic granulomatous disease (X-CGD) in which 
two tandem repeats were used as best combination of miR-126T 
in human HSPCs, and more target sequences resulted in reduced 
transgene expression in differentiated cells.16 We further reduced 
the number of miR-126 target sequences to one in order to achieve 
the highest regulated enzymatic activity in differentiated cells and 
to avoid any possible risk of miR-126 de-targeting from its natural 
targets. Moreover, the low but detectable enzyme activity mea-
sured at +1 day after gene transfer in human HSPCs transduced with 
the regulated LV could also be beneficial to restore cellular func-
tions that may be affected by complete human GALC deficiency in 
patients’ cells with null Galc mutations.15
In order to ameliorate the stability of hGALC long transcript and 
improve enzyme expression in differentiated cells, we took advan-
tage of codon optimization. Recoding the transgene to optimize 
transcription and translation has already been demonstrated to 
improve LVs titers as well as protein production and the efficacy 
of therapies, i.e., for chronic granulomatous disease, hemophilia A 
and B, RAG1 and 2 SCID, and X-linked SCID.16,21–26 Upon codon opti-
mization, while maintaining a high suppression of hGALC expres-
sion in human HSPCs even in the presence of only one miR-126T, 
we could obtain substantially increased enzyme expression, up to 
14-folds over normal donors’ level, in the differentiated progeny of 
BM-derived HSPCs, improving the therapeutic potential of the opti-
mized vector over a noncodon optimized one.
The codon optimized regulated LV was then tested for safety in 
highly transduced human HSPCs in order to assess whether the 
regulation provided by one miR-126 target sequence could pre-
vent toxicity, apoptosis, and/or functional impairment. Importantly, 
transduced CB- and BM-HSPCs plated in semi-solid medium 
showed a normal clonogenic potential in terms of number and 
morphology of generated colonies and of differentiation toward 
Figure 5 Safe hGALC over-expression in murine HSPCs. (a) HSPCs from BM of Twitcher mice (–/–) and wild-type (+/+) mice were transduced with 
hGALCC.O._126T.LV and hARSA.LV, respectively, and plated for liquid culture and clonogenic assay. (a) hGALC activity (n = 10 and 8 pools of donors 
respectively) and (b) VCN (n = 9 and 7 pools of donors, respectively) evaluated after 14 days of liquid culture, and the number (#) of colonies (n = 16 
pools of donors each) (c) retrieved after 2 weeks of growth in semisolid medium are reported (mean ± SEM). Statistical analysis on hGALC activity values 
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Figure 6 Therapeutic efficacy of HSPC-based gene therapy with hGALCC.O._126T.LV in Twitcher mice. (a) Kaplan–Meier survival curves of Twitcher 
mice transplanted with either -/- HSPCs transduced by hGALCC.O._126T.LV (n = 9 transplanted mice) or +/+ HSPCs transduced by hARSA.LV (n = 12 
transplanted mice) and untreated affected controls (UT) (n = 36 mice). Mice survival over day 40 (deaths up to this phase are expected as consequence 
of the conditioning regimen) are shown. UT mice survived on average 43 ± 3 days (maximal survival, 50 days); -/- hGALC_126T mice: 53 ± 9 days (maximal 
survival, 70 days); +/+ hARSA mice: 57 ± 9 days (maximal survival, 73 days). Log-rank (Mantel-Cox) test for curves comparison: -/- hGALC_126T versus 
UT P = 0.0002; hARSA versus UT P < 0.0001; -/- hGALC_126T versus +/+ hARSA P = ns. Comparison of overall survival was done by one-way analysis of 
variance with Bonferroni posttest: -/- hGALC_126T versus UT P < 0.0001; +/+ hARSA versus UT P < 0.0001; -/- hGALC_126T versus +/+ hARSA P = ns. (b) 
hGALC activity measured in the indicated tissues is reported for -/- hGALC_126T (n≥6) and +/+ hARSA (n ≥ 4) long-lived (≥47 days) mice. (c) Pearson’s 
positive correlations between VCN retrieved in the BM of -/- hGALC_126T mice and hGALC activity measured in brain (Pearson r = 0.91, P = 0.012, n = 6) 
and spinal cord (Pearson r=0.97, P = 0.001, n = 6), and correlation between VCN in the BM and survival of -/- hGALC_126T mice (Pearson r = 0.92, P = 0.01, 
n = 6) are reported. Lines represent linear regression of data (brain: r2 = 0.83; spinal cord: r2 = 0.95; survival: r2 = 0.84). (d) Walking patterns of a 
representative gene therapy–treated mouse and controls were recorded, as reported in methods. (e) Quantification of lectin+ area on tissue sections 
from cortex, cerebellum, pons, and sciatic nerve of untreated +/+ (n = 4), -/- (n = 4), -/- hGALC_126T (n = 6), and +/+ hARSA (n = 3). (f) Quantification of 
GFAP area on tissue sections from cortex, cerebellum and pons of untreated +/+ (n = 4), -/- (n = 4), -/- hGALC_126T (n = 6) and +/+ hARSA (n = 3). For 
(e and f), an average of ≥3 sections from each area were evaluated for each mouse. Statistical analysis for (e and f) was performed with one-way analysis 
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B/CFU-E and CFU-M/GM lineages. This result is superimposable to 
what was obtained on CB-derived HSPCs upon transduction with 
the four target sequences-regulated LV expressing murine GALC.14 
This preserved cell functionality was also corroborated by the lack 
of evidence of up-regulation of apoptotic markers in the transduced 
cells, as assessed by cytofluorimetric analysis, 1 day after transduc-
tion. Consistently, sphingolipid measurement in BM-derived HSPCs 
transduced with the hGALCC.O._126T.LV failed to demonstrate accu-
mulation of proapoptotic species shortly after transduction and 
upon in vitro differentiation. Since sphingolipid metabolism is in 
constant flux with the balance between pro- and antiapoptotic 
metabolites determining cellular fate (concept known as “sphingo-
lipid rheostat”27–30), these data suggest that the amount of sphin-
golipids produced by human GALC in human HSPCs transduced 
with the optimized construct could be efficiently managed by 
downstream enzymes able to bring them back to well tolerated 
levels, thus avoiding the induction of apoptosis. To further con-
firm these data and exclude any other perturbation at a molecu-
lar level, a gene expression analysis was performed on transduced 
BM-derived HSPCs. No significantly down- or upregulated tran-
scripts were found shortly after transduction with hGALCC.O._126T.
LV with respect to control LV. Moreover, the supervised analyses 
identified two main branches, untransduced and LV-transduced 
cells, independently from the gene carried by the vector. Among 
the transduced cells the hGALC and hARSA samples cluster accord-
ing to donors, remarking that the hGALC- and hARSA-transduced 
cells show a comparable expression profile.
Once confirmed the safety and tolerability of hGALC expression 
driven by hGALCC.O._126T.LV in vitro, transplantation studies were 
performed to assess transduced human HSPCs functionality in vivo. 
Importantly, also in the challenging in vivo setting of human/mouse 
chimeras, BM-derived HSPCs transduced with the regulated LV dem-
onstrated their full functionality by successful engraftment in NSG 
mice and multilineage differentiation as control LV-transduced cells.
Given the positive results obtained in human HSPCs, the 
hGALCC.O._126T.LV was tested in a severe murine model of GLD to 
prove its potential to produce a functional protein able and suffi-
cient to clear pathologic storage and attenuate disease manifesta-
tions. The vector was used to safely transduce murine HSPCs that 
were then transplanted in lethally irradiated Twitcher neonates. The 
transplant resulted in efficient delivery of the corrective enzyme by 
the progeny of transplanted cells to neural and not-neural tissues, 
with positive correlation of enzyme activity with transduced cell 
engraftment and in a clear phenotype amelioration. A significant 
improvement in the lifespan of the treated mice, as compared to 
untreated Twitcher animals, was achieved as a proof-of-concept of 
enzyme functionality, and correlation of survival with transduced 
cell engraftment was shown. This prolonged survival, which is simi-
lar to what was obtained by transplanting HSPCs from wild-type 
donors, was associated to clearance of undegraded material and 
reduction of the astrogliosis in the brain of treated animals. Despite 
the level of enzyme expression measured in the culture progeny 
of murine HSPCs transduced with the codon optimized hGALC 
 regulated LV is superimposable to what obtained with a murine 
GALC-encoding LV regulated by 4 miR-126 target sequences, the 
advantage of gene-corrected HSPCs over their wild-type counter-
part previously observed in Trs mice using the regulated LV encod-
ing murine Galc cDNA14 was not demonstrated. This difference 
could be due to the choice of a more challenging disease animal 
model (the Twitcher mouse, a total Galc knock out, as compared 
to Trs mice that have some residual enzyme activity) characterized 
by a more rapidly progressing disease. Moreover, hGALC codon 
optimized mRNA sequence could be translated with less efficiency 
in murine cells, being optimized on human tRNAs abundance, and 
the resulting human enzyme could lead to unfavorable interactions 
with murine activators and microenvironment. Of note, even if HSC 
gene therapy employing this or the previously tested LV14 allowed 
to significantly delay disease progression, this treatment alone, at 
least in the severe animal models of the disease, did not definitely 
prevent or halt disease progression, since mice still die with GLD 
symptoms. This is due to the complexity and rapid progression of 
the disease that will likely benefit from combinatorial approaches, 
as tested by others and us.31,32
In conclusion, we here demonstrated the safe and effective profile 
of our miR-126 regulated LV in driving high and functional human 
GALC expression in the progeny of both human and murine HSPCs, 
without impairing their viability and functionality. We expect that 
Krabbe HSPCs could benefit even more from this approach for 
the low but detectable enzyme activity measured soon after gene 
transfer that could restore cellular functions and for the sustained 
therapeutic activity achieved in the differentiated progeny that 
could promote high extent of surrounding cells cross-correction. 
Altogether, these findings provide a strong rationale for consider-
ing this LV the best candidate for the clinical translation of an ex vivo 
gene therapy approach for GLD.
MATeRIAlS AND MeTHODS
Lentiviral vector production and titration
VSV-pseudotyped third-generation LVs were produced by cotransfection of 
transfer, packaging (pMD2.Lg/p.RRE and pRSV.Rev), and envelope constructs 
(pMD2.G) into 293T cells, as previously described.33 The following trans-
fer constructs were used: pCCLsin.cPPT.hPGK.hARSA.Wpre; pCCLsin.cPPT.
hPGK.hIDUA.Wpre. hGALC cDNA was originally provided by Dr Y. Eto and 
cloned in the LV alone (pCCLsin.cPPT.hPGK.hGALC.Wpre) or followed by one 
(pCCLsin.cPPT.hPGK.hGALC_1xmiR126T.Wpre), two (pCCLsin. cPPT.hPGK.
hGALC_2xmiR126T.Wpre), or four (pCCLsin.cPPT.hPGK.hGALC_4xmiR126T.
Wpre) miR-126 target sequences (miR-126T:GCATTATTACTCACGGTACGA). 
Codon optimized hGALC sequence (hGALCC.O) was synthesized (GeneArt 
Gene Synthesis; Life Technologies, Carlsbad, CA) and cloned in the LV 
with a downstream one miR-126 target sequence (pCCLsin.cPPT.hPGK.
hGALCC.O_1xmiR126T.Wpre).
Mouse studies
FVB-Twitcher (FVB/Twi) mice were generated in our animal research facility 
by breeding heterozygous Twitcher (+/−) C57BL6 mice (Jackson Laboratory, 
Bor Harbor, ME) with wild-type (+/+) FVB mice. These mice referred to as 
Twitcher mice in this study have been previously described.31,34,35 Procedures 
were performed according to protocols approved by the Animal Care and 
Use Committee of the Fondazione San Raffaele (IACUC #425, 573) and 
communicated to the Ministry of Health and local authorities. Mice geno-
typing was performed on DNA from tail biopsies as described.36 NOD.
Cg-PrkdcscidIl2rgtm1WjI/SzJ (NSG) mice were purchased by Jackson Laboratory.
Isolation, transduction, and transplantation of human CD34+ cells
Human bone marrow (BM)–derived HSPCs were purchased (2M-101C; 
Lonza, Verviers, Belgium) and prestimulated for 24 hours in CellGro medium 
(CellGenix, Freiburg, Germany) supplemented with hIL-3 (60 ng/μl), hTPO 
(100 ng/μl), hSCF (300 ng/μl), hFlt3-L (300 ng/μl) (all of them from Peprotech, 
Hamburg, Germany) and transduced with two hits of LV at MOI 100 as 
described.13
Human cord blood (CB)-derived HSPCs were either freshly purified from 
human cord blood after obtaining informed consent and on approval 
by the San Raffaele Hospital Bioethical Committee, or purchased from 
Lonza (2C-101). Cells were either prestimulated for 12 hours with the stan-
dard CB-HSPCs cytokine cocktail (hIL-6 (20 ng/μl), hTPO (20 ng/μl), hSCF 
(100 ng/μl), hFlt3-L (100 ng/μl)) in StemSpan serum-free medium (StemCell 
Technologies, Vancouver, British Columbia, Canada) and transduced with 
two hits of LV at MOI 100 (ref. 17) or prestimulated for 24 hours and trans-
duced following BM-HSPCs protocol previously described. Untransplanted 
BM- and CB-derived HSPCs were kept in culture for 14 days in IMDM medium 
9
Gene therapy for globoid cell leukodystrophy
S Ungari et al.
Molecular Therapy — Methods & Clinical Development (2015) 15038Official journal of the American Society of Gene & Cell Therapy
(Sigma Aldrich, St Louis, MO), 10% FBS (Euroclone, Pero, Italy), penicillin 
100 U/ml and streptomycin 100 µg/ml, l-glutamine 2 mmol/l, and cytokines 
(hSCF (300 ng/μl), hIL3 (60 ng/μl), hIL6 (60 ng/μl)).
For NSG experiments, human BM-derived HSPCs were prestimulated 
and transduced with the indicated LVs. After transduction, 3 × 105 cells were 
washed and infused into the tail vein of sublethally irradiated (176 cGy - Rad 
Gil EN 60601- 1, Gilardoni, Mandello del Lario, Italy) 7–9-week-old female 
NSG mice. After 12 weeks, mice were sacrificed and BM, spleen, thymus, and 
liver were harvested and analyzed for lineages composition.
Isolation, transduction, and transplantation of murine 
hematopoietic cells
Young adult mice (4–8 weeks) were sacrificed with CO2, and BM was har-
vested by flushing femurs, tibias, and humerus. Murine HSPCs were purified 
(StemSep Mouse Hematopoietic Progenitor Cell Enrichment Kit; StemCell 
Technologies) and transduced in StemSpan serum-free medium supple-
mented with cytokines (mSCF (5 ng/ml), mFlt3L (10 ng/ml), mIL3 (10 ng/
ml), mIL6 (20 ng/ml); all purchased from Peprotech) with LVs as previously 
described.37 Transduced cells (7.5 × 105 cells/mouse) were intravenously 
(jugular vein) injected into 7-day-old lethally irradiated (612 rad) -/-Twitcher 
mice. After 3 days, mice were injected intraperitoneally with 5 × 106 BM 
mononuclear cells from -/-Twitcher mice as supportive cells. Untransplanted 
murine HSPCs were kept in culture for 14 days in RPMI medium (Sigma), 
10% FBS (Euroclone), penicillin 100 U/ml and streptomycin 100 µg/ml, l-glu-
tamine 2 mmol/l, and cytokines (mSCF (5 ng/ml), mFlt3L (10 ng/ml), mIL3 
(10 ng/ml), mIL6 (20 ng/ml); Peprotech).
Colony-forming cell assay
After transduction, HSPCs were washed, counted, and seeded at a density of 
800 cells/ml (human) or 7,000 cells/ml (murine) in semi-solid medium (human 
MethoCult, H4434; murine Methocult, M3434; StemCell Technologies). After 
14 days, colonies were scored and counted.
GALC activity
GALC activity was determined as previously described.38
Quantitative PCR
Genomic DNA was extracted from liquid culture samples with QIAamp DNA 
Blood Mini kit (Qiagen, Hilden, Germany), from liver (<100 mg) with QIAamp 
MIDI kit (Qiagen) and from brain and spinal cord tissues (<100 mg) by using 
TRI Reagent (Sigma). Quantitative PCR analysis was performed on at least 
50 ng of total genomic DNA as described.17,39 The number of LV copies per 
cell (VCN) was calculated by the following equation: (ng LV/ng endogenous 
DNA) × (no. of LV integrations in the standard curve) × (sample ploidy/stan-
dard ploidy).
Immunofluorescence analysis
Mice were deeply anesthetized with 2,2,2-Tribromoethanol (Sigma) and 
intracardially perfused with 0.9% NaCl. Brains and sciatic nerve tissues were 
collected, equilibrated for 24 hours in 4% PFA followed by 48-hour incuba-
tion in 20 and 30% sucrose in D-PBS. After embedding in Tissue-Tek O.C.T. 
compound (Sakura, Torrance, CA) and deep-freezing on dry ice, tissues were 
cut in serial sagittal and transverse 14-μm-thick cryostat slices for brain and 
sciatic nerve, respectively. Sections mounted on SuperFrost slides (Thermo 
Scientific, Waltham, MA) were washed for 5 minutes in D-PBS and incubated 
with blocking solution (D-PBS, 10% goat serum, 0.3% Triton X-100) for 2 
hours. The primary antibodies anti-GFAP (1:100, MAB3402; Millipore, Billerica, 
MA) and Lectins from Bandeiraea simplicifolia (Griffonia simplicifolia)-FITC 
(10 μg/ml; Sigma) were diluted in blocking solution. After incubation for 
12 hours at 4 °C, sections were washed 3× with D-PBS and stained for 1 
hour with secondary antibody goat antimouse IgG (1:500; Alexa Fluor 546; 
Molecular Probes, Eugene, OR) in D-PBS 10% goat serum and 0.1% Triton 
X-100. Nuclei were stained for 8 minutes at room temperature with ToProIII 
(1:1,000; Molecular Probes) in D-PBS. Sections were washed three times with 
D-PBS and mounted with FluorSave (Calbiochem, San Diego, CA). Samples 
were analyzed using a Zeiss Axioskop2 microscope using double laser con-
focal microscopy with Zeiss Plan-Neofluar objective lens (Zeiss, Arese, Italy). 
Images were acquired using a Radiance 2100 camera (Bio-Rad, Segrate, Italy) 
and LaserSharp 2000 acquisition software (Bio-Rad) and analyzed by Adobe 
Photoshop CS4 software (Adobe, San Jose, CA). For computer-aided image 
analysis, Image J software (NIH Image, Bethesda, MD) was used to quantify 
GFAP+ and lectin+ signal on images—size (pizel^2) 0–9.9999, circularity 
0.00–1.0, measurements: pixel counts, total signal positive area (reported in 
graph), and average pixel size.
Flow cytometric analysis
Human cells from liquid culture or cells from tissues of transplanted NSG 
mice were resuspended in FACS blocking buffer (D-PBS, 1%BSA, 5%FBS 
and Fc Block (1:100; BD Pharmingen, San Diego, CA)) at 4 °C for 15 min-
utes, and then incubated with following antibodies: APC anti-human CD45 
(Invitrogen, Carlsbad, CA) or APC-Cy7 anti-human CD45 (BD Pharmingen); 
RPE anti-human CD34 (Dako, Carpinteria, CA) or Pe-Cy7 anti-human CD34 
(BD Biosciences); APC anti-human CD38 (BD Pharmingen), Pacific blue 
anti-human CD19 (Invitrogen), PE anti-human CD13 (BD Pharmingen), 
Amcyan anti-human CD3 (BD Biosciences, San Jose, CA), RPE anti-human 
CD4 (Invitrogen), Pacific blue anti-human CD8 (Invitrogen); FITC anti-human 
CD15 (BD Biosciences) at 4 °C for 20 minutes. Cells were then washed and 
resuspended in fixing solution (D-PBS, 1% paraformaldehyde, and 2% FBS) 
and analyzed by FACS LSRII (BD Biosciences). 5,000–10,000 events were 
scored. Results were analyzed by FlowJo 8.5.3 software (Tristar, Ashland, OR).
7AAD/annexin V staining
Annexin V–PE apoptosis detection kit (BD Pharmingen) was used to detect 
early apoptotic cells. Human HSPCs were washed with D-PBS and resus-
pended in Binding Buffer solution at the concentration of 106 cells/ml and 
labeled following manufacturer’s protocol. 7-Amino-actinomycin D (7AAD; 
BD Pharmingen) was also added to the cells to distinguish among live 
(7AAD−, AnnexinV−), early apoptotic (7AAD−, AnnexinV+), late apoptotic 
(7AAD+, AnnexinV+), and necrotic (7AAD+, AnnexinV−) cells. Samples were 
analyzed by flow cytometry with FACS LSRII (BD Biosciences) within 1 hour, 
and results were analyzed by the Flow-Jo 8.3 software (Tristar).
Lipidomic analyses
The lipid analyses of cell samples were performed by mass spectrom-
etry according to the Standard Operating Procedures (SOP), the Lab 
Method Sheets (LMS), and data Processing Method Sheets (PMS) of Zora 
Biosciences Oy (Espoo, Finland).40 In brief, lipids were extracted from cell 
suspensions using a modified Folch lipid extraction, reconstituted in 
chloroform:methanol (1:2, v/v) and synthetic external standards are post-
extract spiked to the extracts. Total protein concentration of cell samples 
was determined using the Micro BCA Protein Assay Kit (Thermo Scientific) 
according to the manufacturer’s instructions, and the absorbance of the 
samples is measured at 560 nm by Multiskan EX (Thermo Scientific). Lipids 
were analyzed on a hybrid triple quadrupole/linear ion trap mass spectrom-
eter (5500 QTRAP; AB SCIEX, Foster City, CA) equipped with an ultra-high 
pressure liquid chromatography (UHPLC) system (CTC HTC PAL autosam-
pler and Rheos Allegro pump (Flux Instruments, Basel, Switzerland)) using 
multiple reaction monitoring (MRM)–based method in negative ion mode 
according to the corresponding LMS. The mass spectrometry data files were 
processed using MultiQuant 2.0 (AB SCIEX) for producing a list of lipid names 
and peak areas. Lipids were normalized to their respective internal standard 
and sample volume. The concentrations of molecular lipids are presented as 
pmol/μg total protein.
Gene expression analyses
Affymetrix microarray analysis was used for transcriptional profiling. RNA was 
isolated from the BM-derived HSPCs by the RNeasy Plus Mini kit (Qiagen), 
reverse transcribed with a GeneChip 3′ IVT Express kit, and hybridized to 
Affymetrix HG-U133 Plus 2.0 GeneChip arrays (both from Affymetrix, Santa 
Clara, CA). Hybridization, staining, and scanning were carried out by standard 
Affymetrix protocols. Fluorescence signals were recorded by a GeneChip scan-
ner 3000 (Affymetrix), and image analysis was performed with the GeneChip 
Operating Software (Affymetrix). All data analyses were performed in R, using 
Bioconductor libraries and R statistical packages. The robust multiarray aver-
age procedure was used to convert probe signals into expression values. 
Specifically, the intensity scores were adjusted for the background and nor-
malized by quantile normalization. Log2 expression values were calculated 
using median polish summarization and the custom definition files for Human 
Gene U133 Plus 2.0 arrays, based on Entrez (18 185 Entrez genes, version 12; 
available at: http://brainarray.mbni.med.umich.edu/Brainarray/default.asp). 
Cluster analysis was carried out using probe sets reannotated with custom def-
inition files, to ensure unequivocal probe-to-gene assignment. Differentially 
expressed genes were identified using DNA-Chip Analyzer software (dChip; 
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available at: http://www.dchip.org) by selecting transcripts for which the dif-
ference in the level of expression between the two groups yielded a P value of 
0.05 in a unsupervised and supervised analysis.
Walking abilities
Mice were colored at their upper paws with black Indian ink and lower paws 
with red Indian ink and were let walking in a corridor on a white sheet.
Statistical analysis
Analyses were made by one-way analysis of variance for repeated measure-
ments using Bonferroni’s test for post hoc analysis. For pairwise comparisons, 
an unpaired Student’s t-test was used. All analyses were performed using 
GraphPad Prism 5.0 (GraphPad Software, San Diego, CA).
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